Inhalation Platform TFF’s Thin Film Freezing technology enables inhalable formulations across multiple molecules, presenting a broad collaboration opportunity with large pharma partners seeking novel pulmonary delivery and improved bioavailability.

Lead Candidates Two lead inhalation programs Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder offer touchpoints with infectious disease and transplant markets, creating targeted sales angles for antifungal therapies and immunosuppressant delivery.

Strategic Partnerships Active partnerships with Emory Healthcare, Cleveland Clinic, BARDA, and ongoing collaboration prospects suggest a favorable track record for co-development and funding opportunities to accelerate clinical programs.

Financial Capability With a funding runway of around 73 million and a recent public offering, TFF is positioned to support ongoing clinical milestones, enabling joint development deals, licensing, and milestone-based partnerships.

Market Readiness Clinical-stage focus with proof-of-concept data in transplant and infectious disease spaces, combined with a growing press footprint and leadership hires, signals readiness for commercial discussions with strategic acquirers or co-development partners.